durvalumab + tremelimumab + enfortumab vedotin

Combination of three drugs for cancer therapy: **durvalumab** (anti-PD-L1 monoclonal antibody), **tremelimumab** (anti-CTLA-4 monoclonal antibody), and **enfortumab vedotin** (nectin-4-directed antibody-drug conjugate linked to the cytotoxic agent monomethyl auristatin E, a microtubule inhibitor). Mechanistically, durvalumab and tremelimumab act as immune checkpoint inhibitors that enhance T-cell mediated anti-tumor immune responses, while enfortumab vedotin targets nectin-4-expressing cancer cells, delivering the cytotoxic MMAE payload to induce cell death. Developed to provide perioperative treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer undergoing radical cystectomy, this combination aims to harness dual immune checkpoint blockade plus targeted cytotoxicity for greater antitumor effect than monotherapy or dual combinations[1][3][4][5].

Other names

durvalumab + tremelimumab + enfortumab vedotin